Corporate Social Responsibility

Adhere To The Principle Of Sustainable Development To Create A Better Life

March 2024

Published Time:

2025-04-24

Through a collaboration with Bayer, we have obtained the exclusive license for the domestic development, commercialization, and production of an oral drug for COPD. This drug works by inhibiting prolyl endopeptidase (PREP) activity, thereby preventing the production of COPD inflammatory mediators, and is expected to bring new treatment strategies for COPD patients.